This Scientist Stands To Make Billions With Custom Gene-Edit

Benjamin Oakes' Scribe Therapeutics is developing specialized Crispr proteins for multiple diseases–and it’s got deals with Big Pharma potentially worth over $4 billion

Related Keywords

United States , California , Berkeley , Brett Staahl , Johns Hopkin Modell , Kazi Helal , Joshua Modell , Behzad Aghazadeh , Greg Yap , Deanonymize Blockchain , Benjamin Oakes , Andreessen Horowitz , Jennifer Doudna , Johns Hopkins School Of Medicine , Doudna Lab , Vertex Pharmaceuticals , Broad Institute , Pfizer , University Of California , Benjamin Oake Scribe Therapeutics , Big Pharma , Nobel Prize , David Savage , Crispr Therapeutics , Johns Hopkins School , Oake Scribe , Avoro Ventures , Entrepreneurial Fellowship , Scribe Therapeutics , Svetlana Lucas , Johns Hopkin , Startup Wants To Deanonymize , Privacy Advocates Are , ,